Published guidance, NICE advice and quality standards

Showing 251 to 260 of 2382

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)	TA436	22 March 2017	22 March 2017
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)	TA353	26 August 2015	26 August 2015
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer	TA214	23 February 2011	23 February 2011
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	TA263	22 August 2012	22 August 2012
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	TA285	22 May 2013	22 May 2013
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer	TA212	15 December 2010	15 December 2010
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer	TA284	22 May 2013	22 May 2013
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)	TA560	20 February 2019	20 February 2019
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse	IPG669	4 March 2020	4 March 2020
Bile acid malabsorption: colesevelam	ESUOM22	29 October 2013	29 October 2013